Celgene Corporation (CELG) is Atwood & Palmer Inc.’s 8th Largest Position

Atwood & Palmer Inc. raised its holdings in Celgene Corporation (NASDAQ:CELG) by 3.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 167,170 shares of the biopharmaceutical company’s stock after purchasing an additional 5,920 shares during the quarter. Celgene Corporation makes up about 3.4% of Atwood & Palmer Inc.’s investment portfolio, making the stock its 8th largest position. Atwood & Palmer Inc.’s holdings in Celgene Corporation were worth $21,710,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. State Street Corp raised its position in shares of Celgene Corporation by 2.3% during the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after acquiring an additional 723,844 shares during the last quarter. Jennison Associates LLC raised its position in shares of Celgene Corporation by 1.2% during the second quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock worth $1,742,301,000 after acquiring an additional 156,864 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Celgene Corporation by 4.9% during the first quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock worth $1,255,309,000 after acquiring an additional 472,067 shares during the last quarter. Pioneer Investment Management Inc. raised its position in shares of Celgene Corporation by 15.7% during the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after acquiring an additional 710,584 shares during the last quarter. Finally, Clearbridge Investments LLC raised its position in shares of Celgene Corporation by 24.1% during the first quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock worth $572,617,000 after acquiring an additional 892,392 shares during the last quarter. Hedge funds and other institutional investors own 79.39% of the company’s stock.

In other Celgene Corporation news, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ernest Mario sold 18,506 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the sale, the director now directly owns 69,424 shares in the company, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,733 shares of company stock worth $5,259,359. Company insiders own 0.95% of the company’s stock.

A number of research firms have recently weighed in on CELG. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 target price for the company in a research report on Thursday, August 10th. UBS Group AG (USA) downgraded Celgene Corporation from a “strong-buy” rating to a “market perform” rating and set a $160.00 price objective for the company. in a report on Thursday, October 26th. BMO Capital Markets dropped their price objective on Celgene Corporation from $163.00 to $148.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Mizuho reiterated a “buy” rating on shares of Celgene Corporation in a report on Friday. Finally, Canaccord Genuity set a $156.00 price objective on Celgene Corporation and gave the company a “buy” rating in a report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the stock. Celgene Corporation has a consensus rating of “Buy” and an average target price of $139.64.

COPYRIGHT VIOLATION NOTICE: “Celgene Corporation (CELG) is Atwood & Palmer Inc.’s 8th Largest Position” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/11/04/celgene-corporation-celg-is-atwood-palmer-inc-s-8th-largest-position.html.

Shares of Celgene Corporation (NASDAQ CELG) opened at $100.04 on Friday. The stock has a market capitalization of $77.31 billion, a PE ratio of 15.34, a P/E/G ratio of 0.76 and a beta of 1.79. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52.

Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.58 earnings per share. equities research analysts anticipate that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit